Arrowhead Research | ARWR - Ebitda


Arrowhead Research reported $64.2M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 4.77B 1.11B Dec/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
TG Therapeutics USD 32.69M 5M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -51.05M 55.28M Dec/2025